Advanced Malignant Neoplasms | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Cancerous tumors are classified as malignant neoplasms. Cells prosper when they grow and divide more frequently than is normal. Cancerous tumors have the potential to spread to nearby tissues as well as distant areas of the body. Over the past 50 years, malignant melanoma incidence has rapidly increased globally, with populations with light skin and regions close to the equator experiencing the disease at the highest rates. Treatments like surgery or gamma knife radiation can relieve symptoms and control the disease locally in patients with lone or acutely symptomatic brain metastases. For patients with advanced cutaneous melanoma, drug therapy is used as an adjunctive treatment because surgery is the primary treatment for the disease.

Description

The unchecked, abnormal growth of cells within the human body is known as cancer or malignant neoplasm. Common names for these cells include cancer, malignant, and tumor cells. These cells attack various body parts, organs, blood vessels, etc. because they have characteristics that are quite different from those of normal cells. Numerous factors, which can occur in almost any part of the body, can cause this abnormal cell growth. The cells can also move to different parts of the body and trigger uncontrolled growth there. Malignant tumors can spread to nearby tissues and distant parts of the body. Treatment options may include surgery, chemotherapy, or radiation therapy. Early detection is very important, so be sure to attend all recommended cancer screenings.

Advanced Malignant Neoplasms (Epidemiology)

Over the past 50 years, malignant melanoma incidence has rapidly increased globally, with populations with light skin and regions close to the equator experiencing the disease at the highest rates. Malignant neoplasms generally fall under one of five categories:

Carcinomas: Carcinomas, which account for about 90% of all cancer cases, develop in epithelial tissue, such as the skin or organ linings. Common carcinomas include malignant tumors of the skin, breast, prostate, bladder, cervix, endometrium (uterine lining), lung, colon, and rectum.

Sarcomas: The connective tissues, such as the muscles, tendons, bones, cartilage, and fat, are where this type of cancer first develops. Sarcomas tend to affect young adults more frequently than many other cancer types. Soft tissue sarcoma is the most prevalent variety.

Myelomas: This kind of cancer, also known as multiple myeloma, develops in the plasma cells (immune cells) of the bone marrow. Smoldering (early, precancerous stage) and active (cancerous stage) are the two main types of myelomas.

Leukemias: Leukemias, also known as blood cancers, are bone marrow cancers. Anemia, exhaustion, and issues with blood clotting are all symptoms of this disease that are frequently linked to an excess of immature blood cells.

Lymphomas: The lymphatic system's glands or nodes are where this type of cancer grows. While lymphomas can appear anywhere on the body, they are most frequently felt as lumps in the neck, underarm, or groin areas.

Advanced Malignant Neoplasms -Current Market Size & Forecast Trends

Representing a broad therapeutic area, the market for malignant neoplasms is estimated at $130 billion in 2023, with a projected CAGR of ~9%, reaching $364 billion by 2035, driven by advancements in personalized medicine.

Treatments like surgery or gamma knife radiation can ease symptoms and control the disease locally in patients with single or acutely symptomatic brain metastases. Drug therapy is used as an adjunctive treatment for patients with advanced melanoma because surgery is the primary treatment option for cutaneous melanoma. Less than 50% of patients with primary deep (4 mm) or regional lymph node involvement have long-term disease-free survival; as a result, these patients are categorized as high-risk and adjuvant therapy should be considered. For melanoma that has nodes present, several adjuvant treatments are available. Whether the tumor has the BRAF V600 mutation is a crucial factor in treatment decision-making. BRAF and BRAF/MEK inhibitor combinations can help some patients' diseases advance more slowly. Current National Comprehensive Cancer Network (NCCN) recommendations call for single-agent immunotherapy using the programmed cell death 1 (PD-1) inhibitors pembrolizumab or nivolumab for patients who do not have a BRAF mutation (e.g., wild-type BRAF). Targeted therapy is the first option when an early response is clinically necessary for patients with BRAF mutations, and the NCCN recommends targeted combination therapy with dabrafenib/trametinib or vemurafenib/cobimetinib. Current targeted therapies (e.g., inhibit BRAF) or ease the restrictions placed on the immune response, causing the tumor to shrink (e.g., block PD-1). The adjuvant use of interferon alfa-2b following circumcision in patients who are disease-free but at risk of recurrence was approved in 1995. Pegylated interferon and high-dose interferon alfa-2b have been shown to improve relapse-free survival, but they did not increase overall survival. Unless there is a contraindication to the use of PD-1 inhibitors or a combination of BRAF/MEK inhibitors, this service is not currently provided to patients.

Report Highlights

Advanced Malignant Neoplasms - Current Market Trends

Advanced Malignant Neoplasms - Current & Forecasted Cases across the G8 Countries

Advanced Malignant Neoplasms - Market Opportunities and Sales Potential for Agents

Advanced Malignant Neoplasms - Patient-based Market Forecast to 2035

Advanced Malignant Neoplasms - Untapped Business Opportunities

Advanced Malignant Neoplasms - Product Positioning Vis-a-vis Competitors' Products

Advanced Malignant Neoplasms - KOLs Insight